VANCOUVER, May 22, 2014 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSXV: NVC), today announced financial results for the three months ended March 31, 2014.
"The first quarter of 2014 was marked by major developments at Neovasc," noted Alexei Marko, chief executive officer of Neovasc. "We reported the first implantations of our Tiara(TM) transcatheter mitral replacement valve in humans, presented data at ACC.14 showing that the Neovasc Reducer(TM) improves functional capabilities in refractory angina patients, completed a $25 million bought deal equity financing, received conditional approval for listing on the Toronto Stock Exchange and began trading on the NASDAQ stock exchange, and we accomplished all of this while reporting record revenues and significantly reducing our operating burn."
Help employers find you! Check out all the jobs and post your resume.
